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NICE (the National Institute for Health and Care Excellence) produces a range of advice and guidance on medical
practice and technologies. NICE was established in 1999, and in 2009 set up its Medical Technologies Evaluation
Programme. This assesses new devices in terms of whether their use would offer benefits to the patient and NHS at
a lower cost compared with current practice, or increased benefits for equal cost. NICE evaluates single products
only, as multiple product assessments are time-consuming and mean that manufacturers have to wait longer for
NICE to produce guidance on adoption of their technologies. Research into devices and diagnostics is often sparse
and of low quality as there is little regulation requiring good research in this area. As a result, products are often
not accepted for evaluation, because the evidence base supporting their claimed benefits is so poor.Key points
• Technologies which involve the use of new
procedures need first to be evaluated for NICE
Interventional Procedures Guidance which assess the
safety and efficacy of procedures.
• In order for their product to receive a positive
recommendation in NICE Medical Technologies
Guidance manufacturers must show that their device
provides advantages for patients and/or for the service,
without increasing costs.
• Submissions need to be accompanied by enough
evidence to support the claims.
• Selection of new devices submitted to the NICE
Medical Technologies Evaluation Programme is based
on the proffered evidence context for use and a
plausible cost model.
• NICE also takes into account both expert advice and
patient opinion when evaluating a new device.
• NICE Medical Technologies Guidance focuses on
individual technologies but aims to influence and
improve practice overall.Correspondence: bruce.campbell@nice.org.uk
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In the UK there are various programmes run by NICE
which provide guidance on medical practices and tech-
nologies. These include:
• The Technology Appraisal Programme which
produces guidance based on the clinical and cost
effectiveness of pharmaceuticals and technologies.
• The Clinical Guidelines Programme which produces
guidelines about the management of particular
conditions.
• The Interventional Procedures Programme which
looks at the safety and efficacy of new procedures in
medicine and surgery, and produces guidance on their
use.
• The Public Health Programme which produces
guidance on preventing ill-health.
• The Medical Technologies Programme which looks at
new devices and diagnostics, and produces guidance on
their adoption.
• The Diagnostic Assessment Programme which
evaluates complex and costly diagnostics.
CardioQ
This technology is of special relevance to anaesthetists
and has stimulated the interest of the anaesthetic com-
munity in the National Institute for Health and Care
Excellence (NICE) Medical Technologies guidance. The
guidance on the CardioQ oesophageal Doppler monitor. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ported by evidence of reduced complications, reduced
use of central lines and shorter hospital stays. The guid-
ance says that it should be considered for major high-
risk surgery, where otherwise invasive or intravenous
monitoring would be required.
Origins of the Medical Technologies Programme
The Darzi review of the NHS published in 2008
emphasised a need to simplify the way new technologies
were taken up across the NHS. As a result of this, NICE
was charged with setting up a programme to encourage
adoption of new devices and diagnostics [2]. The aims of
the programme were to identify promising new tech-
nologies, evaluate them using the NICE methods [3],
and then to promote their adoption, if appropriate.
In setting up the Medical Technologies Evaluation
Programme, NICE involved a wide variety of interested
parties including clinicians of all types, different patient
groups, representatives of the medical device industry,
commissioners (payers), health service managers and the
Department of Health (government). A number of basic,
broad principles were agreed for the development of a
very meticulous process. These included:
• The programme should look at novel technologies,
but not to the exclusion of technologies that have been
around for some time but which have not become
widely used;
• It should compare new technologies against current
management;
• The evaluation process should involve two stages:
first deciding whether a technology seems worth
evaluating, and then evaluating it in detail.
For positive Medical Technologies guidance on adop-
tion, the device should not be clinically inferior to
current management, it should be at least as good as or
better than the current practice, and it should be equal
or less in cost compared with current management. The
guidance should be based on single technologies and
products, because multiple technology assessments take
much longer. Finally, the programme should use a ‘cost
consequences’ model in order to determine whether a
new technology is likely to be cost saving and by how
much.
Submitting a new technology for NICE evaluation
Manufacturers can get any device or diagnostic straight
onto the market with the normal regulatory requirement
of a CE mark and scrutiny by the Medicines and
Healthcare products Regulatory Agency (MHRA). How-
ever, if the device involves a new procedure, the safety
and efficacy of that procedure must be reviewed by theNICE Interventional Procedures Committee. By con-
trast, involvement of manufacturers with the NICE Med-
ical Technologies Evaluation Programme is entirely on a
voluntary basis, but it potentially gives them a major ad-
vantage in terms of adoption of their technology, as seen
with CardioQ.
Manufacturers need to produce evidence, particularly
comparative and clinical utility evidence, not only show-
ing that their product works, but that it works in every-
day practice. They must provide as much clinical
evidence as possible on the advantages to patients and/
or the service, as well as defining current management
practices which their technology would replace or alter.
They must outline clear value propositions to allow cost
modelling based on plausible assumptions. In their ini-
tial notification manufacturers are required to answer
several questions in a limited number of words. They
need to provide a clear bulleted list of claims of advan-
tage compared with current management in patient out-
comes or experience; system benefits; and any advantage
for the sustainability (energy saving) agenda.
Factors taken into account in selecting a technology
for detailed evaluation include:
• Improved patient outcomes, quality of life measures
or survival rates;
• Less hospital visits and shorter hospital stays;
• Treating people as outpatients rather than inpatients;
• Better use of resources in terms of hospital facilities;
• Less staff time required when the technology is used;
• Other contributions to cost reduction, including
capital costs and avoidance of treating complications;
• Less waste or less costs from transport or other
energy use.
The value proposition needs to make clear whether
use of the technology is being proposed in the context
of primary or secondary care: either may be possible, but
the value propositions may be radically different. There-
fore manufacturers must consider the care pathway and
make a clear description of the context for which their
product is intended. Failing to provide a cost model with
plausible assumptions is likely to result in a product not
being selected for evaluation.
The decision to evaluate a technology
The NICE process is based on two steps. The committee
first sees the technologies on the basis of a briefing note,
at which point it has relatively limited information on
the product. Based on this and on the advice of experts,
a decision is made whether to select the product for full
evaluation. If a product is selected for evaluation, the
Medical Technologies Advisory Committee then has a
number of options. If the technology appears likely to
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be referred for a NICE Technology Appraisal. If the
product involves a brand new procedure, it will be re-
ferred to NICE Interventional Procedures for evaluation.
If it is a complex diagnostic – in other words for which
there are several alternatives, such as one for which
complex analysis of clinical outcomes will be required,
or one which is likely to increase costs – then it is sent
to the Diagnostics Committee. The most common sce-
nario is one in which a device has claims which can be
evaluated by the Medical Technologies Advisory Com-
mittee, which will then produce guidance on its adop-
tion by the health service.
If a product is not selected for evaluation, the manu-
facturer is sent a letter which includes some of the rea-
sons and which may offer advice about the evidence
which would be needed to support evaluation of the
product.
The NICE evaluation process for medical
technologies
If a technology is selected for evaluation, the manufacturer
then provides the committee with a far more detailed
submission. This submission and the manufacturer’s cost
model are then analysed and critiqued independently
by one of four external academic assessment centres
contracted by NICE.
NICE’s independent Medical Technologies Assessment
Committee, which produces the guidance, is heavily
dependent upon expert advice. Some experts are nomi-
nated by the manufacturer and others by specialist soci-
eties. NICE also requests advice from patients and
patient organisations, and occasionally a patient will
come to the committee to give their personal evidence
where relevant. There is also a wide range of experts on
the committee who provide specialist knowledge in vari-
ous different areas.
When guidance has been drafted it is subject to public
consultation via the NICE website. All NICE guidance
goes through a month of public consultation, receiving
varying amounts of feedback. Every single comment
from the public is considered by the Committee. Public
consultation is a very important part of the evaluation
process and sometimes results in extensive revisions of
the guidance. After further checking by NICE, the guid-
ance is published as NICE Medical Technologies
Guidance.
Limitations of the evidence
One problem with developing this kind of guidance is
that the evidence on devices and diagnostics, compared
to pharmaceuticals, is typically sparse and often poor in
quality. This is because, unlike with drugs, there is little
regulatory demand for good research on technologies.Another factor is that the UK MedTech industry com-
prises around 1,000 large companies and 3,000 smaller
enterprises, many of which have limited resources and
limited experience in research. Furthermore, because
NICE is usually evaluating technologies at an early stage
of their market life, the amount of research (especially
related to any long term outcomes) may be very sparse.
As a result of all these considerations NICE takes a per-
missive approach to the evidence, which may include
use of data from audits, conference abstracts and unre-
ported technical studies, in addition to peer reviewed
publications.
What has NICE achieved so far?
NICE has published a number of anaesthesia-related
guidelines and CardioQ is a recent example. NICE guid-
ance states that using the CardioQ device results in
fewer complications, shorter hospital stays and quicker
recovery. Using a complex cost model, which takes into
account the costs of any changes in the care pathway
where necessary, NICE has estimated a saving of around
£1,100 per patient by changing to CardioQ [1].
Another technology recommended for adoption in
NICE Medical Technologies guidance is the Inditherm
warming mattress [4], which helps to prevent periopera-
tive hypothermia. There was sufficient evidence to sup-
port the claim that the Inditherm mattress may produce
fewer complications and is easier to use than forced air
warming. NICE calculated that adopting this technique
instead of forced air warming could save approximately
£11,000 per operating theatre [5].
NICE guidance focuses on single products, but it also
aims to influence practice overall. For example, it is
hoped that the NICE guidance on CardioQ will help to
influence the overall management of perioperative fluid
balance by monitoring cardiac output.
Potential risks to manufacturers
Not all of NICE guidance is positive. For example, a de-
vice designed to give photodynamic therapy at home for
small skin tumours had very limited evidence, and its
adoption was therefore not recommended in the guid-
ance [6]. Manufacturers may reasonably fear that if guid-
ance does not support their device because of poor
evidence it will have a negative effect on sales of their
product and perhaps on their reputation. They can avoid
this risk by providing a reasonable amount of good
supporting evidence for their product. Indeed, one aim
this kind of NICE’s medical technologies guidance is to
encourage better evidence on devices and diagnostics. It
is important to note that negative guidance does not
mean that a product cannot be used and it may be
suitable for a future evaluation if the evidence base is
improved.
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notified to NICE, with some supporting evidence but
their capacity to work in practice in an NHS context
and to deliver the claimed benefits, is uncertain. Along-
side the Medical Technologies Programme, NICE has
created a means of facilitating research in a UK setting.
This involves creating partnerships between manufac-
turers and appropriate academics and health service
researchers. After further research has been undertaken,
the product is re-evaluated for NICE guidance.
NICE’s contracted external academic centres engage
with manufacturers to facilitate this research. These ex-
ternal assessment centres translate the submission into a
research protocol, introducing manufacturers to inter-
ested academic centres and hospitals in the UK. Once
the research is completed, the external assessment
centre then analyses it in order to see whether the rele-
vant questions have been answered. This analysis is in-
dependent of the manufacturers, even though they may
have funded the research, in part or in full. An example
is a new trial resulting from NICE recommendations,
which is testing a new form of ultrasound treatment de-
livered through a saline mist with the aim of enhancing
the healing of chronic wounds [5].
It is hoped that in the long-term, the pressure to prof-
fer adequate evidence may help to influence manufac-
turers to conduct more and better clinical trials of new
devices. NICE is currently in the process of setting up a
system similar to its scientific advice service for drugs,
whereby companies pay a modest sum in return for
advice about how to produce appropriate evidence.Conclusions and future NICE developments
NICE Medical Technologies guidance influences prac-
tice by making explicit recommendations based on the
available evidence and by providing clear, balanced
judgements. Importantly, the guidance outlines the
expected advantages of a technology and the context in
which they can be expected. It clearly describes the cost
consequences of using the technology instead of current
management, taking into account all aspects of cost, in-
cluding possible changes to care pathways. NICE’s guid-
ance provides a comparison between the advantages
and cost benefits of new technologies compared with
current methods of practice, in order to reassure com-
missioners and managers about the overall benefit that
new technologies offer to patients and to the NHS.
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